share_log

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Truluck Joseph

SEC ·  Mar 28 06:10
Summary by Futu AI
Joseph Truluck, the Chief Financial Officer of Adial Pharmaceuticals, Inc. (ADIL), was involved in a transaction on March 25, 2024. The specific details of the transaction, including the action type, status, number of shares involved, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The report also did not provide information on the number of shares held by Truluck after the transaction. Investors are advised to seek additional information to fully understand the impact of this event on their investment decisions.
Joseph Truluck, the Chief Financial Officer of Adial Pharmaceuticals, Inc. (ADIL), was involved in a transaction on March 25, 2024. The specific details of the transaction, including the action type, status, number of shares involved, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The report also did not provide information on the number of shares held by Truluck after the transaction. Investors are advised to seek additional information to fully understand the impact of this event on their investment decisions.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.